Goldman Sachs Crushes Q2 Expectations with Record Trading Revenue and SpaceX IPO Boost
Revenue jumped 39% to $20.34B while EPS hit $20.98, crushing Wall Street forecasts.
Already have an account? Sign in.
Revenue jumped 39% to $20.34B while EPS hit $20.98, crushing Wall Street forecasts.
Xos secures its first U.S. Air Force contract to build a military-grade Xos Hub mobile charging system, marking its entry into defense.
Topline data from Amylyx’s Phase 3 LUCIDITY trial of avexitide for PBH arrives August 18. Prior results and unmet need fuel optimism.
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.